drugset / Trial / NCT07347626

Eptifibatide for Extended Window Ischemic Stroke After Thrombolysis

NCT07347626

RandomizedParallel-groupSingle-blindTreatment

Summary

This is a multicenter, randomized, open-label, blinded-endpoint clinical trial designed to evaluate the efficacy and safety of early administration of eptifibatide following intravenous thrombolysis in patients with acute ischemic stroke who present 4.5 to 24 hours after symptom onset.

Timeline

Start
2026-03-01
Primary completion
2029-09-30
Completion
2029-12-31

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Eptifibatide Other / unclassified 0.75 ug/kg Intravenous
Comparator Aspirin Small molecule 100 mg
Comparator Clopidogrel Small molecule 75 mg

Indications